Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Embecta Corp. filings document a Nasdaq-listed medical device and medical supplies company with common stock trading under EMBC. Its regulatory disclosures cover operating and financial results, capital-structure information, material-event reports, and governance matters tied to its board, annual meeting and executive-compensation votes.
Recent 8-K reports furnish quarterly and annual results and disclose director changes, board leadership roles and stockholder voting outcomes. Proxy materials describe annual meeting proposals, director elections, auditor ratification, compensation votes, and business context for Embecta's insulin injection franchise, restructuring actions, discontinued patch pump program, and broader medical supplies strategy.
Roth Anthony M. reported acquisition or exercise transactions in this Form 4 filing.
Embecta Corp. reported that VP and Chief Accounting Officer Anthony M. Roth received a grant of 30,000 shares of Common Stock. The award was recorded at a price of $0.00 per share, indicating a compensation-related stock grant rather than an open-market purchase. Following this grant, Roth directly owns 78,833.154 shares of Embecta Common Stock, a figure that also includes shares previously received as stock dividends.
Embecta Corp. filed an Amendment No. 1 to a Schedule 13G/A reporting that River Road Asset Management, LLC beneficially owns 0 shares of Common Stock (CUSIP 29082K105). The amendment lists River Road's address and certifies ownership is 0 shares, representing 0% of the class.
Embecta Corp. has completed its previously announced acquisition of UK-based medical device maker Owen Mumford Holdings Limited. Embecta paid an upfront cash amount of £100 million at closing and may pay up to an additional £50 million if commercial milestones tied to net sales of the Aidaptus® next-generation auto-injector platform are achieved through June 30, 2029.
The deal is intended to accelerate Embecta’s shift from a pure insulin-delivery heritage into a broader medical supplies and drug-delivery platforms business. Owen Mumford adds a portfolio of chronic care and point-of-care devices, strong intellectual property, and device design, molding and assembly capabilities that can be combined with Embecta’s global commercial network and large-scale manufacturing to pursue opportunities across obesity, diabetes, autoimmune diseases and anaphylaxis.
Embecta Corp. Schedule 13G filed reporting passive institutional holdings by Yacktman entities. Yacktman Asset Management LP is reported as beneficial owner of 3,671,877 shares (6.20%) and AMG Yacktman Fund holds 3,000,000 shares (5.07%). The filing states voting and dispositive powers held by the Adviser and identifies the Adviser’s address and CUSIP 29082k105.
The filing attributes shared voting and disposal power to the Adviser under Rule 13d-3 and is signed by authorized representatives with signature dates of 05/05/2026.
Embecta Corp. Schedule 13G filed reporting passive institutional holdings by Yacktman entities. Yacktman Asset Management LP is reported as beneficial owner of 3,671,877 shares (6.20%) and AMG Yacktman Fund holds 3,000,000 shares (5.07%). The filing states voting and dispositive powers held by the Adviser and identifies the Adviser’s address and CUSIP 29082k105.
The filing attributes shared voting and disposal power to the Adviser under Rule 13d-3 and is signed by authorized representatives with signature dates of 05/05/2026.
Embecta Corp. reported weaker results for the quarter ended March 31, 2026, as revenue fell to $221.8 million from $259.0 million, a 14.4% decline. Lower volumes and pricing pressure, especially in pen needles and U.S. markets, reduced gross margin to 57.6% from 63.4% and turned net income of $23.5 million into a net loss of $4.1 million (basic EPS $(0.07)).
For the first six months, revenue declined to $483.0 million, but net income improved to $40.0 million helped by sharply lower restructuring and patch pump-related charges and a $10.1 million gain on asset sales. Operating income for the half rose to $118.3 million.
The company remains highly leveraged with total principal debt of $1.34 billion and a weighted-average interest rate of 6.1%, though it prepaid $75.0 million on its term loan. Embecta agreed to acquire UK-based Owen Mumford for up to £150 million, launched a three-year $100.0 million share repurchase plan, and sharply cut its quarterly dividend from $0.15 to $0.01 per share to conserve cash.
Embecta Corp. reported weaker results for the quarter ended March 31, 2026, as revenue fell to $221.8 million from $259.0 million, a 14.4% decline. Lower volumes and pricing pressure, especially in pen needles and U.S. markets, reduced gross margin to 57.6% from 63.4% and turned net income of $23.5 million into a net loss of $4.1 million (basic EPS $(0.07)).
For the first six months, revenue declined to $483.0 million, but net income improved to $40.0 million helped by sharply lower restructuring and patch pump-related charges and a $10.1 million gain on asset sales. Operating income for the half rose to $118.3 million.
The company remains highly leveraged with total principal debt of $1.34 billion and a weighted-average interest rate of 6.1%, though it prepaid $75.0 million on its term loan. Embecta agreed to acquire UK-based Owen Mumford for up to £150 million, launched a three-year $100.0 million share repurchase plan, and sharply cut its quarterly dividend from $0.15 to $0.01 per share to conserve cash.
Embecta reported weak second quarter fiscal 2026 results and cut its full-year outlook. Q2 revenues were $221.8 million, down 14.4%, with U.S. revenue falling 29.4% and international revenue up slightly on a reported basis. Gross margin declined to 57.6%, and the company posted a net loss of $4.1 million, or $(0.07) per diluted share, versus net income of $23.5 million and $0.40 a year earlier. Adjusted EPS was $0.27, down from $0.70.
For the first six months, revenue was $483.0 million, down 7.3%, with net income of $40.0 million and adjusted EPS of $0.98. Embecta now guides fiscal 2026 revenue to $1,015–$1,035 million and adjusted EPS to $1.55–$1.75, both sharply lower than prior guidance. The updated outlook assumes ongoing U.S. headwinds and includes the pending Owen Mumford acquisition, expected to add about $30 million of revenue and reduce adjusted EPS by roughly $0.15.
The board authorized a three-year $100 million share repurchase program and cut the quarterly dividend from $0.15 to $0.01 per share, reallocating cash toward repurchases and debt reduction. Management still expects to repay about $150 million of debt in 2026. As of March 31, 2026, the company held $193.4 million in cash and equivalents and restricted cash and had $1.342 billion of debt principal outstanding, with no borrowings on its $500 million revolver.
Embecta reported weak second quarter fiscal 2026 results and cut its full-year outlook. Q2 revenues were $221.8 million, down 14.4%, with U.S. revenue falling 29.4% and international revenue up slightly on a reported basis. Gross margin declined to 57.6%, and the company posted a net loss of $4.1 million, or $(0.07) per diluted share, versus net income of $23.5 million and $0.40 a year earlier. Adjusted EPS was $0.27, down from $0.70.
For the first six months, revenue was $483.0 million, down 7.3%, with net income of $40.0 million and adjusted EPS of $0.98. Embecta now guides fiscal 2026 revenue to $1,015–$1,035 million and adjusted EPS to $1.55–$1.75, both sharply lower than prior guidance. The updated outlook assumes ongoing U.S. headwinds and includes the pending Owen Mumford acquisition, expected to add about $30 million of revenue and reduce adjusted EPS by roughly $0.15.
The board authorized a three-year $100 million share repurchase program and cut the quarterly dividend from $0.15 to $0.01 per share, reallocating cash toward repurchases and debt reduction. Management still expects to repay about $150 million of debt in 2026. As of March 31, 2026, the company held $193.4 million in cash and equivalents and restricted cash and had $1.342 billion of debt principal outstanding, with no borrowings on its $500 million revolver.
Embecta Corp. ownership amendment: American Century Capital Portfolios, American Century Investment Management, American Century Companies and Stowers Institute filed an Amendment No. 4 to report beneficial ownership of Common Stock.
The filing lists 1,997,167 shares (3.4%) for American Century Capital Portfolios and 3,439,512 shares (5.8%) for American Century Investment Management / American Century Companies / Stowers Institute, with signatures dated 05/01/2026.
Embecta Corp reports that Vanguard Capital Management beneficially owns 3,004,501 shares of Common Stock, representing 5.07% of the class. The filer reports 440,550 shares with sole voting power and 3,004,501 shares with sole dispositive power. The filing is signed by Ashley Grim on 04/29/2026.
Embecta Corp — The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting zero beneficial ownership of Embecta Corp common stock, listing 0 shares and 0% ownership. The filing states this reporting change follows an internal realignment of Vanguard and related subsidiaries in accordance with SEC Release No. 34-39538.
The amendment identifies Vanguard's separate reporting by subsidiaries and notes that The Vanguard Group, Inc. no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The form is signed by a Vanguard official on 03/26/2026.
Embecta Corp. has agreed to acquire UK-based medical device maker Owen Mumford Holdings Limited in a transaction valued at up to £150 million. Embecta will pay £100 million in cash at closing, plus up to £50 million in additional payments tied to net sales of the Aidaptus® auto-injector platform through the three-year period following closing.
Owen Mumford generated net revenue of £69.4 million during its fiscal year 2025 and brings a portfolio of drug-delivery and chronic care devices that complement Embecta’s diabetes-focused franchise. Embecta expects the deal to support revenue growth from fiscal year 2027 onward, be accretive to adjusted operating income after fiscal year 2027, and generate a high-single-digit return on invested capital by year four.
The transaction, unanimously approved by Embecta’s board, is structured as a share acquisition for 100% of Owen Mumford’s equity and is expected to close in Embecta’s fiscal third quarter of 2026, subject to regulatory approvals and customary conditions. Embecta plans to fund the upfront purchase price with borrowings under its revolving credit facility.